News | Oncology Diagnostics | July 27, 2016

LiverMultiScan to Eliminate Unnecessary Biopsies in Children with Liver Disease

New grant will help U.K.-Poland consortium adapt non-invasive, 15-minute MRI scan to pediatric patients

LiverMultiScan, liver disease diagnosis, children, pediatric patients, U.K., Poland, Kids4LIFe consortium

July 27, 2016 — A U.K-Poland consortium was recently awarded a €1.1M grant to develop a magnetic resonance imaging (MRI)-based medical device to diagnose liver disease in children. Such a device could save children in the future from having to undergo biopsies.

One in five children in Europe suffer from fatty liver disease, but clinical symptoms only surface at later stages when treatment options are limited. Early detection would have a massive impact on how this disease is managed, but the current diagnostic is a painful, invasive biopsy. "Liver biopsy is important for making diagnosis of various liver diseases and is frequently used in follow up to make decisions on therapy. We try to decrease indications for liver biopsy in children because it can cause complications and needs sedation and anesthesia," explained Prof. Piotr Socha, from the Children's Memorial Health Institute in Warsaw, Poland.

LiverMultiScan uses a painless, 15-minute MRI scan which characterizes liver tissue. Developed by Perspectum Diagnostics in Oxford, U.K., this test already has regulatory clearance for use in adults to aid physicians in diagnosing early liver disease.

Supported by funding from EUREKA/Eurostars, the Kids4LIFe consortium will develop and validate LiverMultiScan specifically for patients under 16. In a clinical trial, children who would normally undergo liver biopsy as part of their usual care will also be offered a LiverMultiScan. The information gathered from this study will help the consortium understand how and when the technology is best used in the diagnosis of pediatric liver disease.

As part of the project, a cloud-based health data management system will be developed by the Polish telemedicine company Silvermedia. This platform will allow rapid transfer of liver scans, as well as other health information and diagnostic test results, between local pediatricians and experts in other cities and countries.

LiverMultiscan is now installed in medical institutions on three continents. Used in the clinical management of patients with chronic liver disease, the technology offers a quantitative liver assessment in a safe, non-invasive 15-minute MRI scan. Analysis is based on assessment of native properties of liver tissue, accurate measurement of liver fat and other metrics. The technology is currently being used to assess primary endpoints in clinical trials for investigational therapies to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

LiverMultiScan is manufactured by Mirada Medical, and has CE-marking and U.S. Food and Drug Administration (FDA) clearance.

For more information: www.perspectum-diagnostics.com

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...
Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Two brain metastases from primary lung cancer are contrast enhanced in the brain of a 61-year-old male. Speakers at AHRA 2019 will state that ProHance and other macrocyclic MR agents present a very low risk to patients. Images courtesy of Bracco

Feature | Contrast Media | July 18, 2019 | By Greg Freiherr
Macrocyclic contrast agents have the best safety profile of all the magnetic resonance (MR) contrast media that are n
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
AAPM 2019 Features More Than 40 Presentations on ViewRay's MRIdian MRI-guided Radiotherapy
News | Image Guided Radiation Therapy (IGRT) | July 16, 2019
ViewRay Inc. announced that the company's MRIdian System is the focus of more than 40 abstracts selected by the...
FDA Approves Bayer's Gadavist Contrast for Cardiac MRI in Adult Coronary Artery Disease Patients
Technology | Contrast Media | July 15, 2019
The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic resonance...
FDA Clears Koios DS Breast 2.0 AI-based Software
News | Ultrasound Women's Health | July 11, 2019
Koios Medical announced its second 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Insightec's Exablate Neuro Approved With GE Signa Premier MRI in U.S. and Europe
News | Focused Ultrasound Therapy | July 10, 2019
GE Healthcare and Insightec announced U.S. Food and Drug Administration (FDA) approval and CE mark for Insightec’s...
SimonMed Imaging Implements ProFound AI for 3-D Tomosynthesis
News | Mammography | July 10, 2019
Arizona-based SimonMed Imaging announced their implementation of the first U.S. Food and Drug Administration (FDA)-...
Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden
News | Neuro Imaging | July 05, 2019
Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American...